Free Trial

Ocuphire Pharma (OCUP) Competitors

Ocuphire Pharma logo

OCUP vs. MCRB, RANI, ANRO, RMTI, OPTN, ALLK, DERM, ACET, PDSB, and PRTG

Should you be buying Ocuphire Pharma stock or one of its competitors? The main competitors of Ocuphire Pharma include Seres Therapeutics (MCRB), Rani Therapeutics (RANI), Alto Neuroscience (ANRO), Rockwell Medical (RMTI), OptiNose (OPTN), Allakos (ALLK), Journey Medical (DERM), Adicet Bio (ACET), PDS Biotechnology (PDSB), and Portage Biotech (PRTG). These companies are all part of the "pharmaceutical preparations" industry.

Ocuphire Pharma vs.

Seres Therapeutics (NASDAQ:MCRB) and Ocuphire Pharma (NASDAQ:OCUP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, community ranking, valuation, earnings, dividends and media sentiment.

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 15.0% of Ocuphire Pharma shares are owned by institutional investors. 5.1% of Seres Therapeutics shares are owned by company insiders. Comparatively, 8.7% of Ocuphire Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Seres Therapeutics received 491 more outperform votes than Ocuphire Pharma when rated by MarketBeat users. Likewise, 72.13% of users gave Seres Therapeutics an outperform vote while only 69.81% of users gave Ocuphire Pharma an outperform vote.

CompanyUnderperformOutperform
Seres TherapeuticsOutperform Votes
528
72.13%
Underperform Votes
204
27.87%
Ocuphire PharmaOutperform Votes
37
69.81%
Underperform Votes
16
30.19%

Ocuphire Pharma has higher revenue and earnings than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Ocuphire Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seres Therapeutics$374K331.97-$113.72M-$0.60-1.37
Ocuphire Pharma$16.45M0.00-$9.99M-$0.49N/A

In the previous week, Seres Therapeutics had 3 more articles in the media than Ocuphire Pharma. MarketBeat recorded 7 mentions for Seres Therapeutics and 4 mentions for Ocuphire Pharma. Ocuphire Pharma's average media sentiment score of 0.13 beat Seres Therapeutics' score of -0.27 indicating that Ocuphire Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Seres Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ocuphire Pharma
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Seres Therapeutics has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, Ocuphire Pharma has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500.

Seres Therapeutics has a net margin of 0.00% compared to Ocuphire Pharma's net margin of -85.75%. Seres Therapeutics' return on equity of 0.00% beat Ocuphire Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Seres TherapeuticsN/A N/A -46.67%
Ocuphire Pharma -85.75%-30.19%-27.55%

Seres Therapeutics currently has a consensus price target of $5.08, indicating a potential upside of 520.07%. Ocuphire Pharma has a consensus price target of $16.00, indicating a potential upside of 0.00%. Given Seres Therapeutics' higher possible upside, equities analysts clearly believe Seres Therapeutics is more favorable than Ocuphire Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Seres Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Ocuphire Pharma
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25

Summary

Seres Therapeutics and Ocuphire Pharma tied by winning 9 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCUP vs. The Competition

MetricOcuphire PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$30.33M$7.12B$5.36B$8.41B
Dividend YieldN/A8.77%5.22%4.20%
P/E Ratio-2.3916.07131.5917.70
Price / SalesN/A258.251,438.8478.39
Price / CashN/A50.1639.0633.56
Price / BookN/A5.674.744.57
Net Income-$9.99M$151.16M$115.35M$225.37M

Ocuphire Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCUP
Ocuphire Pharma
2.2617 of 5 stars
N/A$16.00
+∞
N/A$30.33M$16.45M-2.3914High Trading Volume
MCRB
Seres Therapeutics
3.8492 of 5 stars
$0.70
-1.4%
$5.08
+621.1%
-46.0%$119.97M$126.32M-0.60233Upcoming Earnings
RANI
Rani Therapeutics
3.2116 of 5 stars
$2.34
-2.1%
$11.71
+400.6%
+18.4%$117.98M$2.72M-1.98110
ANRO
Alto Neuroscience
2.433 of 5 stars
$4.37
+5.8%
$24.40
+458.4%
N/A$117.48M$210,000.000.00N/AShort Interest ↑
Analyst Revision
High Trading Volume
RMTI
Rockwell Medical
4.1836 of 5 stars
$3.75
+3.9%
$9.00
+140.0%
+118.9%$116.36M$83.61M-22.06300
OPTN
OptiNose
4.0505 of 5 stars
$0.77
-2.5%
$4.00
+418.5%
-40.9%$116.31M$70.99M-2.14190Positive News
ALLK
Allakos
4.7379 of 5 stars
$1.31
+10.1%
$1.67
+27.2%
-32.2%$115.99MN/A-0.56131Short Interest ↓
Positive News
High Trading Volume
DERM
Journey Medical
3.7373 of 5 stars
$5.76
+6.3%
$9.38
+62.8%
N/A$115.28M$77.68M-288.0090Upcoming Earnings
Short Interest ↓
ACET
Adicet Bio
3.2656 of 5 stars
$1.40
-1.4%
$7.50
+435.7%
+3.8%$115.04M$24.99M-0.5590Positive News
PDSB
PDS Biotechnology
1.2239 of 5 stars
$3.12
+0.3%
$14.25
+356.7%
-23.5%$114.44MN/A-2.5620
PRTG
Portage Biotech
2.0722 of 5 stars
$6.36
+2.9%
$120.00
+1,786.8%
-85.5%$113.21MN/A-0.146Positive News

Related Companies and Tools


This page (NASDAQ:OCUP) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners